Peter Cicala

CIK: 0002011534

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ERNA

Ernexa Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

ERNA
Ernexa Therapeutics Inc.
Aug 31, 2026
Award(A)
Stock Option (Right to buy)
Direct
5.9K shares-
ERNA
Ernexa Therapeutics Inc.
Aug 31, 2026
Award(A)
Stock Option (Right to buy)
Direct
5.1K shares-
ERNA
Eterna Therapeutics Inc.
Feb 7, 2025
Award(A)
Stock Option (Right to buy)
Direct
51.5K shares-

		Type	Shares	Price		Ownership
Aug 31, 2026	ERNA Ernexa Therapeutics Inc.	Award(A) Stock Option (Right to buy)	5,943	-	-	Direct
Aug 31, 2026	ERNA Ernexa Therapeutics Inc.	Award(A) Stock Option (Right to buy)	5,083	-	-	Direct
Feb 7, 2025	ERNA Eterna Therapeutics Inc.	Award(A) Stock Option (Right to buy)	51,485	-	-	Direct

1-3 of 3 transactions

About Cicala Peter

Cicala Peter (SEC CIK 0002011534) files insider reports with the SEC as Director of Ernexa Therapeutics Inc. (ERNA).

Signal8 holds 2 ownership filings by Cicala Peter, all Form 4s, filed between Feb 10, 2025 and Sep 1, 2026. Those filings report 3 transactions, from Feb 7, 2025 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cicala Peter's filings is in CAMBRIDGE, MA.

Recent filings by Cicala Peter

Aug 31, 2026: Grants or awards of ERNA derivative securities (2 lines, Form 4, code A).
Feb 7, 2025: Grant or award of ERNA derivative securities (Form 4, code A).

Other insiders filing for Ernexa Therapeutics Inc. (ERNA)

Spiegel Robert J., Director
Bristol James Arthur, Director
Polinsky David, Director
Wexler William A., Director
Ratner Elena, Director
Luther Sanjeev, President and CEO

How to read Form 4 transaction codes